by Truveta staff | Jun 30, 2025 | Research
A new peer-reviewed study from researchers at Saint Luke’s Mid America Heart Institute, Impulse Dynamics, and the Cardiovascular Research Foundation demonstrates the power of real-world data to evaluate device therapies. By evaluating survival outcomes of cardiac...
by Truveta Research | Jun 26, 2025 | Research, Research Insights
Thimerosal is a preservative contained in some vaccines, which has been used and considered safe for decades. During the June 2025 ACIP meeting, a presentation and vote on the use of thimerosal is scheduled to take place. During the 2024-2025 respiratory virus season,...
by Truveta Research | Jun 23, 2025 | Research, Research Insights
Switching from bio-originator Humira to a biosimilar peaked in April 2024 – the month an important formulary change took effect – and remains higher than 2023, suggesting growing adoption of biosimilars. More than 1 in 8 patients who initiated a biosimilar...
by Truveta staff | Jun 19, 2025 | Research
In May 2025, the FDA cleared the first blood test to aid in diagnosing Alzheimer’s disease, making early detection more accessible than ever. The Lumipulse test measures biomarkers in the blood associated with Alzheimer’s pathology, offering a simpler alternative to...
by Truveta Research | Jun 13, 2025 | Research, Research Insights
Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity. Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with...
by Truveta Research | Jun 11, 2025 | Research, Research Insights
Timely receipt of the MMR vaccine for children has been declining since 2021, with just 76.9% of children receiving the MMR vaccine in 2024 on time. The odds of non-vaccination by age two for measles were higher among male children, children in rural areas, White...
